Table 2 Univariate analysis of factors predictive of recurrence-free and overall survival
From: Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma
Factors | No. of patients | MDFSTa (95% CI) | P value | Factors | No. of patients | MOSTb (95% CI) | P value |
|---|---|---|---|---|---|---|---|
Gender | 0.602 | Gender | 0.431 | ||||
Male | 515 | 42.0 (33.4–53.0) | Male | 520 | 178.0 (98.0–NA) | ||
Female | 144 | 34.0 (26.1–71.5) | Female | 145 | 189.0 (67.0–NA) | ||
Ages (years) | 0.167 | Ages (years) | 0.428 | ||||
< 51 | 274 | 50.5 (32.4–72.2) | < 42 | 90 | 189.0 (64.5–NA) | ||
≥ 51 | 385 | 37.5 (28.8–45.6) | ≥ 42 | 575 | 178.0 (106.0–NA) | ||
Hepatitis B or C infection status | 0.722 | Hepatitis B or C infection status | 0.964 | ||||
Negative | 109 | 53.0 (37.5–NA) | Negative | 110 | 193.0 (NA–NA) | ||
Positive | 537 | 38.0 (30.9–49.7) | Positive | 541 | 120.0 (89.0–NA) | ||
Platelet count (× 1000/uL) | 0.49 | Platelet count (× 1000/uL) | 0.026 | ||||
≥ 200 | 165 | 38.0 (21.6–58.0) | ≥ 294 | 43 | 77.5 (29.4–NA) | ||
< 200 | 483 | 39.1 (33.0–53.0) | < 294 | 611 | 178.0 (109.7–NA) | ||
Serum creatinine (mg/dL) | 0.416 | Serum creatinine (mg/dL) | 0.55 | ||||
< 1.2 | 538 | 43.4 (34.0–57.9) | < 1.2 | 542 | 178.0 (125.3–NA) | ||
≥ 1.2 | 60 | 37.5 (20.9–NA) | ≥ 1.2 | 61 | 69.5 (61.2–NA) | ||
Serum albumin (g/dL) | < 0.001 | Serum albumin (g/dL) | < 0.001 | ||||
< 4.0 | 297 | 21.6 (16.0–27.8) | < 4.0 | 300 | 64.2 (49.0–89.0) | ||
≥ 4.0 | 361 | 69.0 (55.4–102.0) | ≥ 4.0 | 364 | 189.0 (178.0–NA) | ||
Serum total bilirubin (mg/dL) | 0.12 | Serum total bilirubin (mg/dL) | 0.049 | ||||
< 1.5 | 592 | 40.0 (32.4–53.0) | < 0.8 | 352 | 193.0 (102.0–NA) | ||
≥ 1.5 | 55 | 28.0 (10.5–69.0) | ≥ 0.8 | 301 | 120.0 (83.8–NA) | ||
Serum AST (U/L) | < 0.001 | Serum AST (U/L) | < 0.001 | ||||
< 48 | 397 | 69.7 (53.0–104.0) | < 46 | 375 | 193.0 (193.0–NA) | ||
≥ 48 | 261 | 20.0 (15.0–28.0) | ≥ 46 | 289 | 59.1 (45.9–67.0) | ||
Serum ALT (U/L) | < 0.001 | Serum ALT (U/L) | < 0.001 | ||||
< 44 | 361 | 58.0 (43.9–86.1) | < 48 | 407 | 189.0 (178.0–NA) | ||
≥ 44 | 297 | 29.0 (21.6–38.6) | ≥ 48 | 257 | 67.0 (56.2–110.0) | ||
Prothrombin time (seconds) | < 0.001 | Prothrombin time (seconds) | < 0.001 | ||||
< 12.4 | 321 | 63.0 (43.4–118.0) | < 12.9 | 392 | 193.0 (NA–NA) | ||
≥ 12.4 | 327 | 31.4 (23.2–39.0) | ≥ 12.9 | 262 | 88.0 (64.5–NA) | ||
Indocyanine green retention rate at 15 min | 0.001 | Indocyanine green retention rate at 15 min | 0.852 | ||||
< 20.3 | 525 | 47.4 (37.5–63.0) | < 12.9 | 290 | 178.0 (89.8–NA) | ||
≥ 20.3 | 112 | 24.5 (18.0–36.7) | ≥ 12.9 | 352 | 120.0 (84.0–NA) | ||
Child–Turcotte–Pugh classification | < 0.001 | Child–Turcotte–Pugh classification | < 0.001 | ||||
A | 606 | 45.5 (37–58.6) | A | 612 | 178 (125.3–NA) | ||
B or C | 50 | 11.9 (6.0–27.7) | B or C | 50 | 14 (9.7–40.2) | ||
Alpha-fetoprotein (ng/mL) | < 0.001 | Alpha-fetoprotein (ng/mL) | < 0.001 | ||||
< 12.6 | 223 | 53.0 (40.3–109.0) | < 16.8 | 261 | 193.0 (193.0–NA) | ||
≥ 12.6 | 426 | 30.2 (24.5–44.7) | ≥ 16.8 | 394 | 98.0 (67.2–NA) | ||
Preoperative TACE | 0.100 | Preoperative TACE | 0.017 | ||||
No | 396 | 51.0 (35.8–79.0) | No | 403 | 178 (178.0–NA) | ||
Yes | 232 | 37.5 (26.2–48.3) | Yes | 231 | 120 (67.2–NA) | ||
Extent of resection | 0.035 | Extent of resection | 0.0052 | ||||
Major | 255 | 31.4 (20.0–47.4) | Major | 257 | 178 (69.5–NA) | ||
Minor | 404 | 45.5 (36.79–61.4) | Minor | 408 | 125 (101.0–NA) | ||
Size of tumor (cm) | < 0.001 | Size of tumor (cm) | < 0.001 | ||||
< 3.6 | 282 | 66.3 (51.0–99.9) | < 5.8 | 447 | 189.0 (178.0–NA) | ||
≥ 3.6 | 377 | 21.5 (16.0–28.8) | ≥ 5.8 | 218 | 46.3 (28.0–83.8) | ||
Tumor number | 0.317 | Tumor number | 0.259 | ||||
Single | 520 | 50.5 (38.6–66.0) | Single | 526 | 189.0 (189.0–NA) | ||
Multiple | 139 | 11.5 (8.8–21.6) | Multiple | 139 | 34.7 (24.4–56.2) | ||
Extent of vascular invasion | < 0.001 | Extent of vascular invasion | <0.001 | ||||
Group A | 326 | 79.0 (66.3–110.0) | Group A | 329 | 193.0 (178.0–NA) | ||
Group B | 191 | 22.4 (19.3–37.2) | Group B | 191 | 73.4 (59.1–114.0) | ||
Group C | 98 | 12.7 (8.0–24.5) | Group C | 101 | 67.2 (34.8–NA) | ||
Group D | 44 | 4.1 (3.6–7.1) | Group D | 44 | 12.0 (7.1–NA) | ||
Intrahepatic metastasis | 0.001 | Intrahepatic metastasis | 0.049 | ||||
Negative | 443 | 58.0 (45.5–75.2) | Negative | 447 | 189.0 (189.0–NA) | ||
Positive | 216 | 14.1 (10.4–20.5) | Positive | 218 | 43.0 (33.2–63.3) | ||
Histologic grading by Edmondson and Steiner’s classification | 0.111 | Histologic grading by Edmondson and Steiner’s classification | 0.004 | ||||
I~II | 370 | 47.4 (37.6–68.9) | Negative | 373 | 178.0 (125.3–NA) | ||
III~IV | 238 | 21.9 (16.0–37.4) | Positive | 241 | 71.4 (59.1–110.0) | ||
Microscopic resection margin | 0.065 | Microscopic resection margin | 0.019 | ||||
Negative | 572 | 45.6 (38.0–60.4) | Negative | 578 | 189.0 (119.8–NA) | ||
Positive | 81 | 8.8 (6.0–19.3) | Positive | 81 | 28.7 (13.2–NA) | ||
Cirrhosis | < 0.001 | Cirrhosis | < 0.001 | ||||
Negative | 288 | 68.9 (43.4–110.0) | Negative | 291 | 193.0 (193.0–NA) | ||
Positive | 325 | 30.4 (22.2–39.9) | Positive | 328 | 89.0 (67.0–NA) | ||
American Joint Committee on Cancer TNM stage | < 0.001 | American Joint Committee on Cancer TNM stage | < 0.001 | ||||
I | 259 | 102.0 (72.2-NA) | I | 262 | 202.0 (NA–NA) | ||
II | 242 | 31.6 (24.1–47.4) | II | 244 | 98.0 (67.2–NA) | ||
III-A | 62 | 8.6 (5.8–21.6) | III-A | 63 | 34.9 (25.6–89.8) | ||
III-B | 37 | 4.1 (3.6–11.1) | III-B | 37 | 9.63 (6.8–NA) | ||
III-C | 53 | 8.0 (4.6–14.1) | III-C | 53 | 18.4 (12.9–83.8) | ||
IV-A | 6 | 9.3 (7.8–NA) | IV-A | 6 | 16.0 (4.67–NA) | ||
LCSGJ TNM stage | < 0.001 | LCSGJ TNM stage | < 0.001 | ||||
I | 76 | 66.0 (51.0–NA) | I | 77 | NA (NA–NA) | ||
II | 324 | 58.6 (45.5–94.4) | II | 325 | 202.0 (202.0–NA) | ||
III | 177 | 20.0 (13.9–39.1) | III | 179 | 64.5 (43.0–178.0) | ||
IV-A | 69 | 5.6 (3.6–9.2) | IV-A | 70 | 13.8 (9.0–27.9) | ||